Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 16Uterine Cervical Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Prostatic Neoplasms 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Neuroendocrine Tumors 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Anus Neoplasms 3Testicular Neoplasms 2Solid Tumor 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Fluorodeoxyglucose F18 × 1 year × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡